In its latest 10-Q for Q1 2026, Radnostix Inc. reported a marked 27% drop in sales driven primarily by two voluntary recalls in its Theranostics segment and a shutdown of cobalt-60 production for critical maintenance. The termination of a previously expected asset sale linked to its Fluorine Products segment has prompted the company to reconsider strategic options for those assets. Despite increased operating expenses and supply chain pressures, Radnostix retains key competitive advantages as the sole U.S. domestic manufacturer of finished cobalt-60 sources with FDA-licensed theranostic products. However, regulatory compliance risks, isotope supply challenges, and distributor uncertainties pose material constraints on near-term growth.